Newron Pharma Buying Hunter-Fleming

Newron Pharmaceuticals SpA (SWX: NWRN) has agreed to acquired Hunter-Fleming Ltd., a UK-based developer of drugs to treat neurodegenerative and inflammatory disorders. The deal includes an upfront payment of EUR 8 million, plus up to EUR 17 million in earnouts (payable in Newron shares). Hunter-Fleming has raised over $20 million in VC funding from firms like Advent International, Equity Ventures Ltd., Yorkshire Fund Managers, MTI Partners and Bridgepoint Capital.